Experienced in Dowling-Meara Epidermolysis Bullosa Simplex

Dr. Harper N. Price

Dermatology | Pediatrics
1919 E Thomas Rd, Main Building, 2nd Floor, Clinic F, 
Phoenix, AZ 
Accepting New Patients
Experienced in Dowling-Meara Epidermolysis Bullosa Simplex
1919 E Thomas Rd, Main Building, 2nd Floor, Clinic F, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical Research

Overview

Harper Price is a Dermatologist and a Pediatrics provider in Phoenix, Arizona. Dr. Price and is rated as an Experienced provider by MediFind in the treatment of Dowling-Meara Epidermolysis Bullosa Simplex. Their top areas of expertise are Epidermolysis Bullosa, Giant Congenital Melanocytic Nevus, Neurocutaneous Melanosis, and Erythema Nodosum. Dr. Price is currently accepting new patients.

Their clinical research consists of co-authoring 52 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article and participated in 1 clinical trial in the study of Dowling-Meara Epidermolysis Bullosa Simplex.

Specialties
Dermatology
Pediatrics
Licenses
Pediatric Dermatology in AZ
Languages Spoken
English

Insurance

Accepted insurance plans

  •  Medica
  •  Humana

Locations

1919 E Thomas Rd, Main Building, 2nd Floor, Clinic F, Phoenix, AZ 85016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2/3, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Response Comparison of the Efficacy and Safety of a Topical Rapamycin Cream for the Treatment of Facial Angiofibromas (FA) Associated With Tuberous Sclerosis Complex (TSC) in Patients 6 Years of Age and Over
A Phase 2/3, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Response Comparison of the Efficacy and Safety of a Topical Rapamycin Cream for the Treatment of Facial Angiofibromas (FA) Associated With Tuberous Sclerosis Complex (TSC) in Patients 6 Years of Age and Over
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug
Study Drug: Rapamycin
Study Phase: Phase 2/Phase 3
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Drug
Study Drug: Oleogel-S10
Study Phase: Phase 3
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Enrollment Status: Terminated
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: VT30
Study Phase: Phase 1/Phase 2
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

51 Total Publications

Granulomatous Variant of Giant Centrifugal Miliaria Profunda in an 8-Month-Old Boy: Expanding the Dermatologic Phenotype of Cardiofaciocutaneous Syndrome.
Granulomatous Variant of Giant Centrifugal Miliaria Profunda in an 8-Month-Old Boy: Expanding the Dermatologic Phenotype of Cardiofaciocutaneous Syndrome.
Journal: Pediatric dermatology
Published: August 10, 2024

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Find Dr. Price's expertise for a condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile